유럽의 백신 보조제 시장 예측(-2030년) : 지역별 분석 - 항원보강제 클래스별, 유형별

The Europe vaccine adjuvants market was valued at US$ 740.50 million in 2022 and is expected to reach US$ 2,051.05 million by 2030; it is estimated to register a CAGR of 13.6% from 2022 to 2030 .

Approvals of Veterinary Vaccine Adjuvants Drive Europe Vaccine Adjuvants Market

Vaccinating animals against common diseases remains the most successful method worldwide to prevent financial and other losses from infectious diseases in animal farming. Regulatory approvals for veterinary vaccine adjuvants are increasing, with manufacturers' growing focus on developing vaccines with greater efficacy and stability. Montanide is one of the known veterinary vaccine adjuvants. The Montanide adjuvant range is based on three core technologies-emulsions, micro-emulsions, and polymers. Therefore, an upsurge in adjuvant approvals for veterinary vaccines accelerates the overall market growth of vaccine adjuvants.

Europe Vaccine Adjuvants Market Overview

The Europe vaccine adjuvant market has been segmented into Germany, UK, France, Italy, Spain, and the Rest of Europe. A few top vaccine manufacturers have a presence in Germany. In December 2022, Evonik launched a plant-based squalene named PhytoSquene to improve vaccine efficacy. It is a non-animal derivative suitable for vaccines and other pharmaceutical applications. PhytoSquene is the first known amaranth oil-derived squalene introduced in the market for adjuvants in drugs indicated for parenteral usage. This latest innovation of Evonik is meant to provide the market with sustainable, non-animal derivative solutions. In 2021, Evonik launched the pharma-grade and plant-derived cholesterol "PhytoChol".

Europe Vaccine Adjuvants Market Revenue and Forecast to 2030 (US$ Million)

Europe Vaccine Adjuvants Market Segmentation

The Europe vaccine adjuvants market is categorized into adjuvant class, type, and country.

Based on adjuvant class, the Europe vaccine adjuvants market is segmented into mineral salt adjuvant, emulsion adjuvant, liposome adjuvant, and others. The mineral salt adjuvant segment held the largest share of the Europe vaccine adjuvants market share in 2022.

By type, the Europe vaccine adjuvants market is bifurcated into human vaccine adjuvant and veterinary vaccine adjuvant. The human vaccine adjuvant segment held a larger share of Europe vaccine adjuvants market in 2022.

By country, the Europe vaccine adjuvants market is segmented into Germany, the UK, France, Italy, Spain, and the Rest of Europe. Germany dominated the Europe vaccine adjuvants market share in 2022.

Croda International Plc; CSL Ltd; Dynavax Technologies Corp; GSK Plc; InvivoGen SAS; Novavax Inc.; Phibro Animal Health Corp; Seppic SA; and SPI Pharma Inc are some of the leading companies operating in the Europe vaccine adjuvants market.

Table Of Contents

1. Introduction

• 1.1 The Insight Partners Research Report Guidance
• 1.2 Market Segmentation

2. Executive Summary

• 2.1 Key Insights

3. Research Methodology

• 3.1 Coverage
• 3.2 Secondary Research
• 3.3 Primary Research

4. Europe Vaccine Adjuvants Market - Key Market Dynamics

• 4.1 Europe Vaccine Adjuvants Market - Key Market Dynamics
• 4.2 Market Drivers
  • 4.2.1 Rising Number of Infectious Disease Outbreaks and Pandemic
  • 4.2.2 Approvals of Veterinary Vaccine Adjuvants
• 4.3 Market Restraints
  • 4.3.1 Product Recalls and Adverse Effects
• 4.4 Market Opportunities
  • 4.4.1 Advancements in Biotechnology and Immunology
• 4.5 Future Trends
  • 4.5.1 Technological Advancements
• 4.6 Impact of Drivers and Restraints:

5. Vaccine Adjuvants Market -Europe Market Analysis

• 5.1 Europe Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
• 5.2 Europe Vaccine Adjuvants Market Forecast and Analysis

6. Europe Vaccine Adjuvants Market Analysis - by Adjuvant Class

• 6.1 Overview
• 6.2 Mineral Salt Adjuvant
  • 6.2.1 Overview
  • 6.2.2 Mineral Salt Adjuvant: Europe Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
• 6.3 Emulsion Adjuvant
  • 6.3.1 Overview
  • 6.3.2 Emulsion Adjuvant: Europe Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
• 6.4 Liposome Adjuvant
  • 6.4.1 Overview
  • 6.4.2 Liposome Adjuvant: Europe Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
• 6.5 Others
  • 6.5.1 Overview
  • 6.5.2 Others: Europe Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)

7. Europe Vaccine Adjuvants Market Analysis - by Type

• 7.1 Human Vaccine Adjuvant
  • 7.1.1 Overview
  • 7.1.2 Human Vaccine Adjuvant: Europe Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
• 7.2 Veterinary Vaccine Adjuvant
  • 7.2.1 Overview
  • 7.2.2 Veterinary Vaccine Adjuvant: Europe Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)

8. Europe Vaccine Adjuvants Market -Country Analysis

• 8.1 Europe
  • 8.1.1 Europe Vaccine Adjuvants Market
    • 8.1.1.1 Germany: Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
      • 8.1.1.1.1 Overview
      • 8.1.1.1.2 Germany: Glucose Monitoring Devices Market - Revenue and Forecast to 2030 (US$ Million)
      • 8.1.1.1.3 Germany: Vaccine Adjuvants Market Breakdown, by Adjuvant Class
      • 8.1.1.1.4 Germany: Vaccine Adjuvants Market Breakdown, by Type
    • 8.1.1.2 United Kingdom: Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
      • 8.1.1.2.1 Overview
      • 8.1.1.2.2 United Kingdom: Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
      • 8.1.1.2.3 United Kingdom: Vaccine Adjuvants Market Breakdown, by Adjuvant Class
      • 8.1.1.2.4 United Kingdom: Vaccine Adjuvants Market Breakdown, by Type
    • 8.1.1.3 France: Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
      • 8.1.1.3.1 Overview
      • 8.1.1.3.2 France: Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
      • 8.1.1.3.3 France: Vaccine Adjuvants Market Breakdown, by Adjuvant Class
      • 8.1.1.3.4 France: Vaccine Adjuvants Market Breakdown, by Type
    • 8.1.1.4 Italy: Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
      • 8.1.1.4.1 Overview
      • 8.1.1.4.2 Italy: Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
      • 8.1.1.4.3 Italy: Vaccine Adjuvants Market Breakdown, by Adjuvant Class
      • 8.1.1.4.4 Italy: Vaccine Adjuvants Market Breakdown, by Type
    • 8.1.1.5 Spain: Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
      • 8.1.1.5.1 Overview
      • 8.1.1.5.2 Spain: Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
      • 8.1.1.5.3 Spain: Vaccine Adjuvants Market Breakdown, by Adjuvant Class
      • 8.1.1.5.4 Spain: Vaccine Adjuvants Market Breakdown, by Type
    • 8.1.1.6 Rest of Europe Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
      • 8.1.1.6.1 Overview
      • 8.1.1.6.2 Rest of Europe Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
      • 8.1.1.6.3 Rest of Europe Vaccine Adjuvants Market Breakdown, by Adjuvant Class
      • 8.1.1.6.4 Rest of Europe Vaccine Adjuvants Market Breakdown, by Type

9. Industry Landscape

• 9.1 Overview
• 9.2 Growth Strategies in the Global Vaccine Adjuvants Market
• 9.3 Organic Developments
  • 9.3.1 Overview
• 9.4 Inorganic Developments
  • 9.4.1 Overview

10. Company Profiles

• 10.1 SPI Pharma Inc
  • 10.1.1 Key Facts
  • 10.1.2 Business Description
  • 10.1.3 Products and Services
  • 10.1.4 Financial Overview
  • 10.1.5 SWOT Analysis
  • 10.1.6 Key Developments
• 10.2 GSK Plc
  • 10.2.1 Key Facts
  • 10.2.2 Business Description
  • 10.2.3 Products and Services
  • 10.2.4 Financial Overview
  • 10.2.5 SWOT Analysis
  • 10.2.6 Key Developments
• 10.3 CSL Ltd
  • 10.3.1 Key Facts
  • 10.3.2 Business Description
  • 10.3.3 Products and Services
  • 10.3.4 Financial Overview
  • 10.3.5 SWOT Analysis
  • 10.3.6 Key Developments
• 10.4 Seppic SA
  • 10.4.1 Key Facts
  • 10.4.2 Business Description
  • 10.4.3 Products and Services
  • 10.4.4 Financial Overview
  • 10.4.5 SWOT Analysis
  • 10.4.6 Key Developments
• 10.5 Dynavax Technologies Corp
  • 10.5.1 Key Facts
  • 10.5.2 Business Description
  • 10.5.3 Products and Services
  • 10.5.4 Financial Overview
  • 10.5.5 SWOT Analysis
  • 10.5.6 Key Developments
• 10.6 InvivoGen SAS
  • 10.6.1 Key Facts
  • 10.6.2 Business Description
  • 10.6.3 Products and Services
  • 10.6.4 Financial Overview
  • 10.6.5 SWOT Analysis
  • 10.6.6 Key Developments
• 10.7 Croda International Plc
  • 10.7.1 Key Facts
  • 10.7.2 Business Description
  • 10.7.3 Products and Services
  • 10.7.4 Financial Overview
  • 10.7.5 SWOT Analysis
  • 10.7.6 Key Developments
• 10.8 Novavax Inc
  • 10.8.1 Key Facts
  • 10.8.2 Business Description
  • 10.8.3 Products and Services
  • 10.8.4 Financial Overview
  • 10.8.5 SWOT Analysis
  • 10.8.6 Key Developments
• 10.9 Phibro Animal Health Corp
  • 10.9.1 Key Facts
  • 10.9.2 Business Description
  • 10.9.3 Products and Services
  • 10.9.4 Financial Overview
  • 10.9.5 SWOT Analysis
  • 10.9.6 Key Developments

11. Appendix

• 11.1 About The Insight Partners